Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 403 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2015', provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bile Duct Cancer (Cholangiocarcinoma) Overview 10
Therapeutics Development 11
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 11
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 12
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 13
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 18
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 22
Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 26
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 27
4SC AG 27
Agios Pharmaceuticals, Inc. 28
Ariad Pharmaceuticals, Inc. 29
ArQule, Inc. 30
Array BioPharma Inc. 31
Arrien Pharmaceuticals, LLC 32
Aslan Pharmaceuticals Pte. Ltd. 33
Bayer AG 34
BIND Therapeutics, Inc. 35
Blueprint Medicines 36
Boehringer Ingelheim GmbH 37
Boston Biomedical, Inc. 38
Bristol-Myers Squibb Company 39
Celgene Corporation 40
CellAct Pharma GmbH 41
Cellceutix Corporation 42
Concordia Healthcare Corp. 43
Cornerstone Pharmaceuticals, Inc. 44
Delcath Systems, Inc. 45
Eisai Co., Ltd. 46
Eli Lilly and Company 47
Exelixis, Inc. 48
F. Hoffmann-La Roche Ltd. 49
Johnson & Johnson 50
Komipharm International Co., Ltd. 51
Loxo Oncology, Inc. 52
Mebiopharm Co., Ltd. 53
MedImmune, LLC 54
Merck & Co., Inc. 55
Merrimack Pharmaceuticals, Inc. 56
NanoCarrier Co., Ltd. 57
NormOxys, Inc. 58
Novartis AG 59
NuCana BioMed Limited 60
OncoTherapy Science, Inc. 61
Ono Pharmaceutical Co., Ltd. 62
Panacea Pharmaceuticals, Inc. 63
PCI Biotech AS 64
Pfizer Inc. 65
Plexxikon Inc. 66
Provecs Medical GmbH 67
Sanofi 68
Senhwa Biosciences, Inc. 69
Spectrum Pharmaceuticals, Inc. 70
Sun Pharma Advanced Research Company Ltd. 71
Threshold Pharmaceuticals, Inc. 72
VasGene Therapeutics, Inc. 73
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Combination Products 75
Assessment by Target 76
Assessment by Mechanism of Action 80
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 87
afatinib dimaleate - Drug Profile 89
AG-120 - Drug Profile 94
ARN-5032 - Drug Profile 96
ARQ-087 - Drug Profile 97
BBI-503 - Drug Profile 98
binimetinib - Drug Profile 100
BLU-554 - Drug Profile 105
cabozantinib s-malate - Drug Profile 106
CAP-7.1 - Drug Profile 110
CC-90007 - Drug Profile 112
cisplatin - Drug Profile 115
CPI-613 - Drug Profile 117
dasatinib - Drug Profile 119
DKN-01 - Drug Profile 122
docetaxel - Drug Profile 124
durvalumab - Drug Profile 127
evofosfamide - Drug Profile 131
gemcitabine hydrochloride - Drug Profile 139
Im-01 - Drug Profile 140
IMB-101 - Drug Profile 141
IMB-102 - Drug Profile 142
infigratinib - Drug Profile 143
JNJ-42756493 - Drug Profile 144
KM-3174 - Drug Profile 146
KML-001 - Drug Profile 150
lenvatinib - Drug Profile 152
LOXO-101 - Drug Profile 158
MBPY-005 - Drug Profile 160
melphalan - Drug Profile 161
merestinib - Drug Profile 164
MK-2206 - Drug Profile 165
napabucasin - Drug Profile 168
nivolumab - Drug Profile 171
NUC-1031 - Drug Profile 178
OCVC-01 - Drug Profile 180
OXY-111A - Drug Profile 181
paclitaxel albumin bound - Drug Profile 183
paclitaxel albumin free - Drug Profile 187
PAN-622 - Drug Profile 189
pembrolizumab - Drug Profile 190
PLX-8394 - Drug Profile 199
ponatinib hydrochloride - Drug Profile 201
porfimer sodium - Drug Profile 204
refametinib - Drug Profile 206
regorafenib - Drug Profile 209
resminostat - Drug Profile 213
RRX-001 - Drug Profile 218
SAR-408701 - Drug Profile 220
seribantumab - Drug Profile 221
silmitasertib - Drug Profile 224
SPI-1620 - Drug Profile 226
sunitinib malate - Drug Profile 228
trametinib dimethyl sulfoxide - Drug Profile 232
Vaccine for Metastatic Cholangiocarcinoma - Drug Profile 235
varlitinib - Drug Profile 236
Vas-01 - Drug Profile 239
vemurafenib - Drug Profile 241
Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 245
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 387
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 389
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 390
Featured News & Press Releases 390
Appendix 398
Methodology 398
Coverage 398
Secondary Research 398
Primary Research 398
Expert Panel Validation 398
Contact Us 398
Disclaimer 399

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2015 15
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 18
Number of Products under Development by Companies, H2 2015 (Contd..1) 19
Number of Products under Development by Companies, H2 2015 (Contd..2) 20
Number of Products under Development by Companies, H2 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2015 22
Comparative Analysis by Late Stage Development, H2 2015 23
Comparative Analysis by Clinical Stage Development, H2 2015 24
Comparative Analysis by Early Stage Development, H2 2015 25
Products under Development by Companies, H2 2015 26
Products under Development by Companies, H2 2015 (Contd..1) 27
Products under Development by Companies, H2 2015 (Contd..2) 28
Products under Development by Companies, H2 2015 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2015 30
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2015 31
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H2 2015 32
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015 33
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H2 2015 34
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H2 2015 35
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 36
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015 37
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2015 38
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BIND Therapeutics, Inc., H2 2015 39
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines, H2 2015 40
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H2 2015 41
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H2 2015 42
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H2 2015 43
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H2 2015 44
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H2 2015 45
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corporation, H2 2015 46
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H2 2015 47
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 48
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H2 2015 49
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co., Ltd., H2 2015 50
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H2 2015 51
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H2 2015 52
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 53
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H2 2015 54
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co., Ltd., H2 2015 55
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology, Inc., H2 2015 56
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co., Ltd., H2 2015 57
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune, LLC, H2 2015 58
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co., Inc., H2 2015 59
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 60
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co., Ltd., H2 2015 61
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys, Inc., H2 2015 62
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H2 2015 63
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H2 2015 64
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H2 2015 65
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 66
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015 67
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech AS, H2 2015 68
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc., H2 2015 69
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Plexxikon Inc., H2 2015 70
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H2 2015 71
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H2 2015 72
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H2 2015 73
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 74
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 75
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 76
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics, Inc., H2 2015 77
Assessment by Monotherapy Products, H2 2015 78
Assessment by Combination Products, H2 2015 79
Number of Products by Stage and Target, H2 2015 81
Number of Products by Stage and Mechanism of Action, H2 2015 85
Number of Products by Stage and Route of Administration, H2 2015 88
Number of Products by Stage and Molecule Type, H2 2015 90
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H2 2015 249
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2015 391
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H2 2015 392
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H2 2015 393